CVRx, Inc. (NASDAQ:CVRX) Shares Sold by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lessened its position in shares of CVRx, Inc. (NASDAQ:CVRXFree Report) by 2.2% during the third quarter, HoldingsChannel reports. The institutional investor owned 28,653 shares of the company’s stock after selling 648 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in CVRx were worth $435,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of CVRx by 1,056.2% in the 2nd quarter. BlackRock Inc. now owns 704,342 shares of the company’s stock valued at $10,875,000 after buying an additional 643,425 shares during the period. Price T Rowe Associates Inc. MD increased its position in CVRx by 2.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 618,649 shares of the company’s stock worth $3,718,000 after buying an additional 14,173 shares in the last quarter. State Street Corp increased its position in CVRx by 1,118.2% during the second quarter. State Street Corp now owns 510,145 shares of the company’s stock worth $7,877,000 after buying an additional 468,269 shares in the last quarter. Emerald Advisers LLC grew its position in shares of CVRx by 1.3% in the third quarter. Emerald Advisers LLC now owns 501,073 shares of the company’s stock valued at $7,601,000 after purchasing an additional 6,419 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of CVRx by 17.7% in the first quarter. Vanguard Group Inc. now owns 463,935 shares of the company’s stock valued at $2,779,000 after purchasing an additional 69,718 shares during the period. Hedge funds and other institutional investors own 56.50% of the company’s stock.

CVRx Stock Up 0.5 %

Shares of CVRx stock opened at $24.81 on Wednesday. The company has a current ratio of 13.99, a quick ratio of 12.52 and a debt-to-equity ratio of 0.17. The business’s 50 day simple moving average is $26.26 and its 200-day simple moving average is $19.75. The stock has a market capitalization of $516.54 million, a price-to-earnings ratio of -12.53 and a beta of 1.50. CVRx, Inc. has a twelve month low of $6.57 and a twelve month high of $33.13.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Piper Sandler upped their price target on CVRx from $21.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Lake Street Capital increased their target price on CVRx from $21.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th. Finally, JPMorgan Chase & Co. increased their price target on CVRx from $31.00 to $36.00 and gave the company an “overweight” rating in a report on Friday, January 26th.

Read Our Latest Report on CVRX

CVRx Company Profile

(Free Report)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.

Featured Stories

Want to see what other hedge funds are holding CVRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVRx, Inc. (NASDAQ:CVRXFree Report).

Institutional Ownership by Quarter for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.